Get started
Work

Caractérisation de la réponse au traitement par nivolumab plus ipilimumab (N+I) ou sunitinib (S) chez des patients (pts) atteints d’un carcinome à cellules rénales avancé (CCRa) non préalablement traité : CheckMate 214

Year: 2018
Type: article
DOI: 10.1016/j.purol.2018.07.033
Authors: B.I. Rini, N.M. Tannir, B. Escudier, D.F. McDermott, M.-O. Grimm, C. Porta, T. Powles, C. Kollmannsberger, H. Gurney, S.S. Tykodi, M. Harrison, D.Y.C. Heng, V. Grünwald, T.K. Choueri, S. Mekan, M.B. McHenry, H.J. Hammers, R.J. Motzer, S. George
Institutions: Cleveland Clinic, The University of Texas MD Anderson Cancer Center, Institut Gustave Roussy, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Jena University Hospital, Queen Mary University of London, Royal Free London NHS Foundation Trust, The Royal Free Hospital, BC Cancer Agency, Westmead Hospital, Macquarie University, University of Washington, Fred Hutch Cancer Center, Duke Cancer Institute, Medizinische Hochschule Hannover, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Bristol-Myers Squibb (United States), The University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, Roswell Park Comprehensive Cancer Center
Language: French
Field: Medicine
Open Access status: closed
OpenAlex ID: W2899504455
FWCI:
Cites:
Cited by:
Related to: 10